Looking for a clinical trial for your CRC patient with at NCT? Or using AI platforms? Texting friends? Let me make your life easier!! Look at the list of trials available at @MoffittNews right NOW or coming soon (*< 6 months) below Keep in mind that this figure does not include an extensive list of clinical trials in the Early Therapeutics department led by @GarridoLagunaMD Feel free to reach out here or at [email protected] for referrals #colorectalcancer #coloncancer @FightCRC @CCAlliance

Great session today at @FLASCO_ORG discussing the complexity of rectal cancer treatment with this amazing team from @MoffittNews

Excellent opportunity to join us at @MoffittNews as GI Med Onc - Clinical Investigator focused on colorectal cancer! Help us to change the future of #colorectalcancer research Apply here: moffitt.wd108.myworkdayjobs.…

A valuable opportunity to join our team in a key position that supports our growing portfolio at @MoffittNews Apply here: moffitt.wd108.myworkdayjobs.…

🚨Portfolio update!! Look at the list of trials available at @MoffittNews right NOW or coming soon (*< 6 months) below. Activating NOW: FOLFIRI/bev +/- pelareorep in 2L RAS mutant CRC (Oncolytics). This is an oncolytic virus that infects RAS mutant cells and has demonstrated promising activity in CRC an anal cancer. Feel free to reach out here or at [email protected] for referrals

Visiting fellows at @MoffittNews this month: the “Brazilian storm”

LinkedIn just reminded me of my four-year anniversary at @MoffittNews . I am eternally grateful to this institution, which welcomed me with open arms from day one. These past few months have been challenging in my new leadership position within the department, yet at the same time, extremely rewarding: I was promoted to Director of Research for the Gastrointestinal Oncology Department, recognized as the physician who recruited the highest number of patients for research protocols across the entire institution, awarded internal grants to help advance several projects, and today, named a “Moffitt Ambassador.” Every single research project brings hope to our patients; if we can share the high-level research conducted at Moffitt, we will be able to reach more people and change more lives!

Trial up and running! DO NOT start 3rd line therapy for KRAS G12D colon cancer patients. Really promissing trial with KRAS inhibitor with ON/OFF activity. Feel free to reach out to refer patients

Are you ready to make a real difference in the fight against cancer? Join Moffitt Cancer Center as a Clinical Research Coordinator and become a vital part of a dynamic, innovative team that’s delivering tomorrow’s cancer treatments—today! Whether your background is in science, healthcare, social sciences, business, or the humanities, this is your chance to bring hope, advance cutting-edge research, and grow your career in a role that truly matters. @MoffittNews Apply here: moffitt.wd108.myworkdayjobs.…

Just got my copy of Scientific Jiu Jitsu. I am really passionate about both cancer science and jiu-jitsu - one drives me to understand disease, better treatments, and push the boundaries of what we know; the other trains the body and mind to solve complex problems under real pressure. Looking forward to seeing how this book bridges the two worlds. #BJJ 🥋🔬

🎯TARGET-D 203 is now open — Phase 2 registration-directed trial of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, for patients with KRAS G12D-mutated metastatic colorectal cancer. Happy to announce the trial has opened at @MoffittNews The study will evaluate VS-7375 in both refractory settings (as monotherapy or + anti-EGFR) and in the first-line setting (with chemo + cetuximab). A new investigational option designed to hit KRAS G12D in both the ON and OFF states — now advancing for patients who need better therapies. Feel free to reach out here or at the email [email protected] to refer patients. #KRAS #ColorectalCancer #TARGETD203 #VS7375 #Moffitt @VerastemOncolog